LifT Biosciences, a British pharmaceuticals company, and Minaris Regenerative Medicine, a German contract development and manufacturing service provider specializing in cell and gene therapies, announced a manufacturing and development partnership on Feb. 16, 2023. Per the terms of the agreement, the companies plan to develop a Good Manufacturing Practice (GMP)-compliant manufacturing process to supply LIfT’s clinical trial programs for its N-LifT cell therapy in Europe; these trials are currently slated to begin in the first quarter of 2024.
